Mode
Text Size
Log in / Sign up
Phase 1 N=60 Randomized Quadruple-blind Prevention

A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine

Influenza, Human

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jan 2019
Primary outcome: Primary: Number of Subjects With Immediate Adverse Events — 0; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Influenza vaccine, split inactivated (Biological); Placebo (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Institute of Virology, Vaccines and Sera, Torlak
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Immediate Adverse Events
0; 0
PRIMARY
Number and Percentage of Subjects With Solicited Local Reactogenicity
2; 0; 14; 4; 6; 0
PRIMARY
Number and Percentage of Subjects With Solicited Systemic Reactogenicity
2; 1; 2; 0; 5; 2
PRIMARY
Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events
2; 4
PRIMARY
Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)
0; 0; 0; 0
SECONDARY
Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.
25; 0; 23; 0; 21; 0
SECONDARY
Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine
30; 10; 30; 19; 26; 5
SECONDARY
Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens
15.97; 21.19; 295.14; 22.32; 37.75; 41.41
SECONDARY
Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.
18.49; 1.05; 11.65; 1.04; 7.25; 0.99
SECONDARY
Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.
24.06; 31.75; 211.12; 40.00; 18.02; 19.77
SECONDARY
Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.
8.77; 1.26; 6.96; 1.23; 4.09; 1.50

Summary

This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or placebo (phosphate buffered saline). A total of 60 healthy male and female adults 18 through 45 years of age will be randomized to receive vaccine (30) or placebo (30).

Eligibility Criteria

Inclusion Criteria

  • Healthy male or female adult 18 through 45 years of age at the enrollment visit.
  • Literate (by self-report) and willing to provide written informed consent.
  • Healthy, as established by the medical history, physical examination, and screening laboratory evaluations.
  • Capable and willing to complete Memory Aids and willing to return for all follow-up visits.
  • For females, willing to utilize reliable birth control measures (e.g., intrauterine device, hormonal contraception, condoms) from Day 0 through the Day 21 visit.

Exclusion Criteria

  • Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.
  • Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 21 visit.
  • Current or recent (within 2 weeks of vaccination) acute illness with or without fever.
  • Receipt of immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 21 visit.
  • Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study vaccination. (For corticosteroids, this means prednisone or equivalent, equal or more than 0.5 mg per kg per day; topical steroids are allowed.)
  • History of asthma.
  • Hypersensitivity after previous administration of any vaccine.
  • Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.
  • History of any blood or solid organ cancer.
  • History of thrombocytopenic purpura or known bleeding disorder.
  • History of seizures.
  • Known or suspected immunosuppressed or immunodeficient condition of any kind.
  • Confirmed hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Known HIV infection (self-report).
  • Known active tuberculosis or symptoms of active tuberculosis, regardless of cause (self-report).
  • History of chronic alcohol abuse and/or illegal drug use.
  • Pregnancy or lactation. (A negative pregnancy test will be required before administration of study product for all women of childbearing potential.)
  • History of Guillain-Barré Syndrome
  • Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02585700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search